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During its intra-erythrocytic growth phase, the malaria parasite Plasmodium falciparum relies heavily 
on glycolysis for its energy requirements. Pyruvate kinase (PYK) is essential for regulating glycolytic 
flux and for ATP production, yet the allosteric mechanism of P. falciparum PYK (PfPYK) remains 
poorly understood. Here we report the first crystal structure of PfPYK in complex with substrate 
analogues oxalate and the ATP product. Comparisons of PfPYK structures in the active R-state and 
inactive T-state reveal a ‘rock-and-lock’ allosteric mechanism regulated by rigid-body rotations of each 
subunit in the tetramer. Kinetic data and structural analysis indicate glucose 6-phosphate is an activator 
by increasing the apparent maximal velocity of the enzyme. Intriguingly, the trypanosome drug suramin 





Plasmodium falciparum is the etiologic agent of the most severe forms of malaria, which caused 
~435,000 deaths in 2017 [1]. During the intra-erythrocytic stage of its life cycle, the malaria parasite  
depends heavily on glycolysis for ATP production[2,3], which makes glycolytic enzymes natural anti-
malaria drug targets [4,5]. The activity of pyruvate kinase (PYK, EC 2.7.1.40) catalyzes the last step of 
glycolysis to produce ATP and is regulated by several physiological effectors. Three allosteric sites 
have been identified in PYKs: the canonical site, which is generally regulated by fructose 1,6-
bisphosphate (F16BP)[6-8], fructose 2,6-bisphosphate (F26BP) [9,10], or AMP [11]; the sugar-
monophosphate site found in mycobacteria [11]; and the amino-acid site found in cancer cells[12,13].  
 Two PYK isoenzymes have been discovered in P. falciparum [4,14]: PYK-I (canonical PYK, 
(UniProtKB C6KTA4) mainly involved in glycolysis and PYK-II that localizes to the apicoplast and 
correlates with lipid synthesis. Here, unless stated otherwise, PfPYK stands for P. falciparum PYK-I. 
About 15 years ago, Chan et al. were first to clone the gene for PfPYK and expressed it as a recombinant 
PfPYK enzyme[15]. However, the kinetic characterization was performed on GST-tagged PfPYK. 
Given its large size (~26 kDa), it is likely that the GST tag partially hindered or affected conformational 
changes occurring in the PfPYK tetramer (~55 kDa per monomer), which are crucial for allosteric 
regulation. So, a structure/function study of the native enzyme remains to be done. Here, we report 
biochemical and structural studies of an untagged PfPYK that reveal a “rock-and-lock” allosteric 
mechanism regulated by rigid-body rotations and a B-domain motion controlled by active-site ligand 
binding. 
 
Results and discussion 
 
Untagged PfPYK protein production 
PfPYK was purified from an Escherichia coli expression system and the N-terminal His6-tag was 
cleaved to generate a fully untagged PfPYK (See Materials and methods). The untagged PfPYK shows 
similar activity to the GST-tagged PfPYK with a kcat value of 248 ± 2.1 s-1 versus 257 s-1, respectively 
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[15] (Table 1). For the substrate phosphoenolpyruvate (PEP), the untagged PfPYK displayed sigmoidal 
kinetics in the absence of effector, with a S0.5 value of 0.33 ± 0.01 mM and a Hill coefficient (h) of 1.4 
± 0.1, indicating positive cooperativity. Likewise, the untagged enzyme showed sigmoidal kinetics with 
respect to its substrate ADP with a S0.5 value of 0.24 ± 0.01 mM and a h of 1.6 ± 0.1. In contrast, the 
GST-tagged PfPYK exhibits hyperbolic kinetics with respect to both substrates under similar assay 
conditions [15]. This difference may be due to the presence of a GST tag in this previous study.  
 
The activation of untagged PfPYK 
We then investigated the enzymatic effects of a series of metabolites on PfPYK (Fig. 1A). In agreement 
with previous findings by Chan et al.[15], we did not observe effects from “canonical” activators such 
as F16BP and F26BP. Interestingly, glucose 6-phosphate (G6P) showed a notable PYK activation, 
while the known inhibitor oxalate (OX) significantly inhibited the enzyme activity (IC50 ~149 µM). The 
binding of G6P and OX, which potentially lock the enzyme in its active state, increased the thermal 
stability of the enzyme (Fig. 1B). In the presence of G6P at a concentration of 5 mM, both the enzyme 
activity (kcat) and the catalytic efficiency (kcat/S0.5) of PfPYK were enhanced by ~1.5-fold without 
affecting the affinity and cooperativity towards the PEP substrate (Table 1; Fig. 1C). This suggests that 
PfPYK could be a V-type allosteric enzyme with respect to G6P. One of the phosphate binding motifs 
at the canonical effector site is highly conserved and is named “PO4-2 motif” (Fig. S1; Table S1). 
Therefore, we performed in silico docking of the activator G6P to the canonical effector site and found 
that the phosphate group of G6P formed a number of favorable interactions with the PO4-2 motif (Fig. 
1D). In contrast, citrate slightly decreased the affinity for the PEP substrate, with no obvious change in 
the apparent kcat (Table 1). It is noteworthy that citrate at 2 mM inhibited GST-tagged PfPYK activity 
by over 90% [16]. 
 
Crystal structure of PfPYK 
The only crystal structure of PfPYK in the inactive T-state was deposited to the Protein Data Bank by 
the Structural Genomics Consortium (SGC) (PDB ID: 3KHD). No report describing the structure and 
allosteric mechanism was published, which might be due to the lack of an active R-state structure for 
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comparison. Here, we successfully determined the crystal structure of PfPYK in the R-state with oxalate 
(substrate PEP analogue) and ATP bound at the active site (Table 2). Similar to other protozoan PYK 
structures [9,17], PfPYK adopts a tetrameric architecture formed by identical subunits with four 
domains (N-terminus, A, B and C domains) (Fig. 2A). The active site is located in the cleft between the 
A-domain and the lid-like B-domain, while the C-domain harbors a canonical effector site. While the 
activator G6P was present in the crystallization buffer, no electron density for the G6P moiety was 
observed. Thus, in the absence of the activator, the effector loop (residues 493-502) was flexible and 
could not be traced with confidence.  
  
Allostery of PfPYK  
The allosteric mechanism was analyzed at the level of quaternary protein structure by superposing the 
R-state tetramer structure (PDB ID: 6KSH) onto the inactive T-state tetramer structure (PDB ID: 
3KHD), excluding the mobile B domains. In agreement with the “rocking motion” mechanism 
identified in human M2PYK[12], as well as PYKs from trypanosomes [9,10,18] and  mycobacteria 
[11], the superposition suggests that each subunit of the tetramer simultaneously undergoes a 9o rigid-
body (AC-core) rotation concomitant with the T- to-R-state transition (Fig. 2B). We next explored the 
determinants of these concerted rigid-body rotations during the allosteric interconversion between the 
T- and R-state (Fig. 2C, D). Similar to trypanosomatid PYKs [9,10,18], several additional hydrogen 
bonds and salt bridges that lock the tetramer in the R-state form across the C-C interface of PfPYK, 
resulting in a larger interface area (Tables S2, S3). Similar interfacial changes were also found at the 
A-A interface. However, as the effector loop from the PfPYK structure was poorly defined in the 
electron density map, we were not able to confirm a role for this effector loop in the observed rigid-
body rotations, if any. Binding of the active-site ligand oxalate triggers a conformational change 
(“rock”) toward its more thermally-stable R-state (“lock”)[9,11]. In PfPYK, when the enzyme was 
mixed with oxalate alone or in the presence of G6P and ATP, the thermal stability increased slightly 
(ΔTm = ~1 oC), suggesting that the R-state conformation is more stable. This agrees with the structurally 
observed additional interface interactions (Fig. 1B).  
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 It is now well established that the lid-like B-domain of PYK can adopt multiple conformations 
regulated by the active-site ligands [9,11]. By superposition of the AC-cores from the R-state (PDB ID: 
6KSH) and T-state monomer (PDB ID: 3KHD), we found that the binding of oxalate and ATP caused 
the B-domain to rotate 40° toward the A-domain compared with the free T-state form (Fig. 3A, B). The 
closed conformation of the B-domain in OX/ATP-bound PfPYK was mainly stabilized by the 
interactions between ATP and the enzyme (Fig. 3C). In the open conformation, the B-domain residues 
Arg109 and Lys191 no longer form interactions with ATP.  
  
Suramin inhibition on PfPYK 
Having established PfPYK kinetics and OX/ATP-bound structure, we next assessed the effect of the 
trypanosome drug suramin [19] on PfPYK in order to explore the possibility of alternative treatments 
for malaria. Suramin was found to inhibit trypanosomatid PYKs by competing with the ADP substrate 
[20], which was also observed  in PfPYK (Fig. 4A, B). The proposed binding mode of suramin shown 
in Fig. 4C could lead to the design of new PfPYK inhibitors. 
 
The design of selective inhibitors against PfPYK was hindered by limited structure illustration and its 
allosteric regulation study. More than 10 years have elapsed since the first crystal structure of PfPYK 
at ligand-free inactive state was reported (PDB ID: 3KHD). Unfortunately, the scientific report of 
PfPYK structure was unavailable in literatures until now. Furthermore, the production of stable and 
active untagged PfPYK seems to be a challenge where the published kinetics of PfPYK was studied in 
its GST-tagged form [15]. Here we report modified protocols for the overexpression and purification 
of untagged PfPYK and its crystallization, which enabled the study of kinetics and determination of its 
X-ray crystal structure in complex with active-site ligands. Remarkably, we have shown evidence for a 
unique V-type activation of PfPYK by non-canonical effector G6P. In addition to our findings in 
trypanosome PYKs [9,10,18], the rigid-body rotation was also found in PfPYK allosteric mechanism. 
However, it is still unclear whether activator G6P is involved in this conformational change due to the 
lack of G6P-bound PfPYK structure.   
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Materials and methods 
 
Details on the enzyme production. kinetics and biophysical analyses can be found in the Supporting 
Information. 
 
Crystallization and data collection 
The crystallisation experiments were performed by the vapour-diffusion method using the hanging-
drop technique at 4 °C. The drops were equilibrated against a reservoir filled with 1 ml well solution. 
To co-crystallise PfPYK with the PEP analogue oxalate (OX), product ATP and activator G6P, 1.0 μl 
protein solution was mixed with 0.5 μl ligand solution (20 mM) and incubated at room temperature for 
1-2 minutes. Then 1.5 μl well solution was added to the mixture for crystallisation. Oxalate is a 
structural analogue of the enolate form of pyruvate and has been generally used in crystallisation 
conditions to stabilise PYK in the active R-state [10,18]. The well solution consisted of 12% PEG 8000, 
10-20% glycerol, 50 mM TEA buffer pH 7.2, 100 mM KCl, 50 mM MgCl2.  
X-ray intensity data for the crystal of PfPYK was collected at the Australian Synchrotron 
(Australia). The dataset was from a single crystal flash-cooled in liquid nitrogen at 100 K. Data were 
then processed with MOSFLM [21] and scaled with AIMLESS [22,23]. The data-collection and 
processing statistics are summarised in Table 2. 
 
Structure determination 
The R-state PfPYK structure was solved by molecular replacement using the program Phaser [24]. The 
initial search model (PfPYK monomer) for the molecular-replacement experiment was obtained from 
the deposited T-state PfPYK (PDB ID: 3KHD). The structure was manually adjusted using Coot [25] 
followed by several cycles of restrained refinement in Autobuster [26]. Where appropriate, water 
molecules and ligands were added to the structure and TLS refinement was applied at later stage of 
refinement. Ligands OX and ATP were clearly identified and modeled, however, G6P density was not 
observed in the structure. 
 9 
The quality of the structures was assessed using the MOLPROBITY server [27], and the figures 
were generated using PyMOL [28]. The data processing and refinement statistics are summarised in 
Table 2. The structure factors and coordinates for PfPYK-OX/ATP have been deposited in the RCSB 
Protein Data Bank as PDB entry 6KSH. 
 
Structure analysis 
The program Superpose [29] in the CCP4 [30] suite was used to calculate the allosteric rigid-body 
rotations and B-domain movements from the superposition of T-state and R-state tetramers as described 
previously [18]. Both RMS differences and rotation matrices were calculated in the superposition 
process [18].  
 
Molecular modelling 
Molecular modelling was employed to explore the interaction between PfPYK and G6P. The receptor 
was prepared in Chimera v1.11.2 [31] by removing water molecules, fixing non-standard residues, and 
adding hydrogen and charges using the ff14SB force field [32]. Then, AutoDock Vina v1.1.2 [33] was 
employed for docking G6P to the effector site. The ligand was treated as flexible while the protein was 
treated as rigid. A search space (25×25×25 Å3) was defined with the centre of mass of ligand in the 
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Table 1. Kinetic properties of PfPYK and the effects of modulatorsa 
 
Ligand Kinetic parameter Modulator 
  None +G6Pb +citrateb 
PEP S0.5 (mM) 0.33 ± 0.01 0.35 ± 0.02 0.41 ± 0.01 
 Hill coefficient, h 1.4 ± 0.1 1.5 ± 0.1 1.4 ± 0.1 
 kcat (s-1) 248 ± 2 383 ± 7 296 ± 3 
 kcat/S0.5 (s-1∙mM-1) 752 1094 722 
ADP S0.5 (mM) 0.24 ± 0.01 ndc nd 
 Hill coefficient, h 1.6 ± 0.1 nd nd 
 kcat (s-1) 246 ± 3 nd nd 
 kcat/S0.5 (s-1∙mM-1) 1025 nd nd 
Suramin IC50 (µM) 128 ± 14 
Oxalate IC50 (µM) 150 ± 11 
 
a Data represent mean ± SD for three replicates 
b The concentrations of modulators are: G6P - 5 mM, citrate - 5 mM 
c nd, not determined 
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Table 2. Data collection and refinement statistics 
 
 PfPYK-OX/ATP 
PDB ID 6KSH 
Data collection  
Space group P 61 2 2 
Cell dimensions  
a, b, c (Å) 139.41, 139.41, 453.16 
α, β, γ (°) 90.00,90.00,120.00 
Solvent content (%) 57 
Resolution (Å) 60.37-2.60 
No. of measured reflectionsa 1695738 (251897) 
No. of unique reflections 81169 (11640) 
Wilson B-factor (Å2) 58.4 
Rmerge (%) 19.0 (131.9) 
I/σI 15.4 (3.1) 
CC (1/2) 0.998 (0.803) 
Completeness (%) 100.0 (100.0) 
Multiplicity 20.9 (21.6) 
Refinement  
Monomers in a.u. 4 
No. reflections 81001 
Rwork / Rfree 0.2072/0.1529 








RMS deviations  
Bond lengths (Å) 0.010 
Bond angles (°) 1.25 
Ramachandran plots  
Favoured (%) 97.5 
Allowed (%) 99.5 
 





Fig. 1. Modulation of PfPYK activity. (A) Regulation of PfPYK activity by small molecules. The 
magenta and black asterisks indicate ligands having the significant impact on enzyme activation or 
inhibition, respectively. Data represent mean ± SD for N=3 experiments. (B) Stabilisation of PfPYK by 
small molecules binding. The Tm values above 73 oC (no ligand) are highlighted. Data represent 
deviation about the mean for N=2. (C) Concentration-response curves observed for titration of PEP 
against PfPYK activity in the absence or presence of G6P. Data represent mean ± SD for N=4. (D) The 
proposed binding mode of G6P at the effector site derived from docking with “AutoDock”. Partial 
amino-acid sequence alignment of the effector site among PYKs is shown above the structure model. 







Fig. 2. Structure of PfPYK and overview of allosteric conformational changes. (A) Overall view 
of the PfPYK tetramer from the crystal structure. Each monomer comprises four domains shown in 
different colours: N-terminus in green (residues 1-28), A-domain in brown (residues 29-105, 204-375), 
B-domain in blue (residues 106-203), C-domain in pink (residues 376-511). The polypeptide chains are 
shown as ribbons while ligands and metals are shown as spheres. (B) Rigid-body rotation occurring 
during the transition between the T- (PDB ID: 3KHD) and R- (PDB ID: 6KSH) state of PfPYK. The 
transition between the T- (grey) and R-state is accompanied by a 9° rigid-body (AC core) rotation 
around the central pivot. (C) Interactions at the C-C interface between subunit 1 and subunit 3 in the R-
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state of PfPYK. Residues from subunit 3 involved in interface interactions are highlighted. (D) 




Fig. 3. B-domain of PfPYK adopts a closed conformation to accommodate active-site ligands. (A) 
Subunits from two PfPYK structures (chain D in each structure) are superposed based on the AC-core, 
to show the relative movements of the B-domains: R-state PfPYK-OX/ATP (PDB ID: 6KSH) and T-
state PfPYK (PDB ID: 3KHD). (B) Enlargement of the catalytic site showing that the B-domain is in a 
closed conformation, when active-site ligands are bound. (C) Active-site interactions in the PfPYK-
OX/ATP structure. The presence of ATP, oxalate and metal ions is documented by an unbiased Fo-Fc 





Fig. 4. The drug suramin inhibits PfPYK by competing with substrate ADP. (A) Dose-dependent 
inhibition of PfPYK by suramin. Data represent mean ± SD for N=4. (B) Concentration–response 
curves observed for titration of ADP against PfPYK activity in the absence and presence of suramin. 
Data represent deviation about the mean for N=2. (C) Suramin and ATP are proposed to share an 
overlapping binding site. OX/ATP-bond PfPYK (PDB ID: 6KSH) was superimposed onto the suramin-
bound Leishmania mexicana PYK (LmPYK; PDB ID: 3PP7) structure, based on superposition of their 
Cα atoms.  
